HRGN Reports No Revenue, Continues Burn Rate in Q2

TL;DR

**HRGN is a pre-revenue biotech burning cash; avoid until clinical milestones are clear.**

AI Summary

Harvard Apparatus Regenerative Technology, Inc. (HRGN) reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net loss for the three months ended June 30, 2025, was not explicitly stated with a dollar amount in the provided data, but the context implies continued operational losses. Key business changes include an increase in common stock shares outstanding to 15,918,979 as of June 30, 2025, from 60,000,000 shares authorized. The company's strategic outlook remains focused on its regenerative medicine pipeline, though specific progress or milestones are not detailed in the provided excerpt. Risks include the ongoing need for significant capital to fund research and development, as evidenced by the lack of revenue generation. The company's accumulated deficit continues to grow, indicating a reliance on external financing to sustain operations.

Why It Matters

For investors, HRGN's continued lack of revenue generation signals that it remains a highly speculative, pre-commercial entity, reliant on future financing rounds. Employees face uncertainty given the company's burn rate and the long development cycles inherent in regenerative medicine. Customers, primarily future patients, are awaiting the successful development and commercialization of its regenerative products, which are still in early stages. The broader market for surgical and medical instruments sees HRGN as a small player attempting to innovate in a highly competitive and capital-intensive space, with significant hurdles to overcome.

Risk Assessment

Risk Level: high — The risk level is high because Harvard Apparatus Regenerative Technology, Inc. reported no revenue for the three and six months ended June 30, 2025, indicating a complete lack of commercial operations. The company's ongoing operational losses and reliance on external financing, without any clear path to revenue generation in the provided data, present significant financial instability.

Analyst Insight

Investors should exercise extreme caution and consider HRGN a highly speculative investment. Monitor for significant clinical trial progress or new financing announcements before considering any position, as the current filing shows no commercial activity.

Financial Highlights

revenue

$0

revenue Growth

0.00%

Revenue Breakdown

Key Numbers

• $0 — Revenue (for the three and six months ended June 30, 2025, indicating no commercial sales.)
• 15,918,979 — Common Stock Shares Outstanding (as of June 30, 2025, reflecting the current equity structure.)
• 60,000,000 — Authorized Common Stock Shares (indicating the maximum shares the company can issue.)

Key Players & Entities

• Harvard Apparatus Regenerative Technology, Inc. (company) — filer of the 10-Q
• SEC (regulator) — recipient of the 10-Q filing
• $0 (dollar_amount) — revenue for Q2 2025
• 15,918,979 (dollar_amount) — common stock shares outstanding as of June 30, 2025
• 60,000,000 (dollar_amount) — authorized common stock shares
• June 30, 2025 (date) — end of the reporting period
• Bloomberg (company) — financial news outlet

FAQ

Risk Factors

• Lack of Revenue and Need for Capital [high — financial]: The company reported $0 revenue for the three and six months ended June 30, 2025. This lack of commercial sales indicates a continued reliance on external financing to fund research and development and sustain operations, as evidenced by the growing accumulated deficit.
• Accumulated Deficit [high — financial]: The company's accumulated deficit continues to grow, reflecting ongoing operational losses and the absence of revenue. This necessitates significant capital infusions to support its regenerative medicine pipeline and future development.
• Dependence on R&D Pipeline [medium — operational]: The company's strategic focus is on its regenerative medicine pipeline. However, the lack of revenue and detailed progress updates suggests significant execution risk and uncertainty regarding the commercial viability of its research efforts.

Industry Context

Harvard Apparatus Regenerative Technology operates in the regenerative medicine sector, a field characterized by high R&D investment and long development cycles. The industry is highly competitive, with numerous companies vying for funding and regulatory approvals for novel therapies. Success hinges on scientific breakthroughs, clinical trial outcomes, and effective commercialization strategies.

Regulatory Implications

As a company in the regenerative medicine space, HRGN faces stringent regulatory oversight from bodies like the FDA. Approval processes for new therapies are lengthy and costly, with a high failure rate. Any delays or setbacks in regulatory pathways can significantly impact the company's financial health and development timeline.

What Investors Should Do

1. Monitor R&D Pipeline Progress
2. Assess Future Financing Needs
3. Review Shareholder Dilution

Key Dates

• 2025-06-30: Quarterly Report (10-Q) Filing — Provides an update on the company's financial performance and operational status for the second quarter of 2025.
• 2025-08-11: 10-Q Filing Date — Indicates the official submission date of the Q2 2025 10-Q filing to the SEC.

Glossary

Accumulated Deficit

The cumulative net losses of a company since its inception, minus any net profits. It represents a negative retained earnings balance. (Indicates the company has incurred more expenses than revenues over its history, highlighting its need for ongoing financing.)

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently held by all its shareholders. (Reflects the current equity structure and ownership base of the company.)

Authorized Common Stock Shares

The maximum number of shares of common stock that a company is legally permitted to issue, as specified in its corporate charter. (Sets the upper limit on the company's ability to raise capital through equity issuance.)

Year-Over-Year Comparison

The company reported $0 revenue for the three and six months ended June 30, 2025, which is consistent with the prior year periods, indicating no commercial sales have been achieved. The number of common stock shares outstanding has increased to 15,918,979 as of June 30, 2025, from 60,000,000 authorized shares, suggesting potential equity issuances or adjustments. No new significant risks were detailed in the provided excerpt, but the ongoing lack of revenue and reliance on R&D remain persistent concerns.

Key Financial Figures

• $0.01 — 8,979 shares of common stock, par value $0.01 per share, outstanding. Table of Conte

Filing Documents

• hrgn20250520c_10q.htm (10-Q) — 917KB
• ex_821564.htm (EX-31.1) — 8KB
• ex_821565.htm (EX-31.2) — 8KB
• ex_821566.htm (EX-32.1) — 5KB
• ex_821567.htm (EX-32.2) — 5KB
• 0001437749-25-025939.txt ( ) — 4545KB
• hrgn-20250630.xsd (EX-101.SCH) — 40KB
• hrgn-20250630_cal.xml (EX-101.CAL) — 30KB
• hrgn-20250630_def.xml (EX-101.DEF) — 280KB
• hrgn-20250630_lab.xml (EX-101.LAB) — 249KB
• hrgn-20250630_pre.xml (EX-101.PRE) — 304KB
• hrgn20250520c_10q_htm.xml (XML) — 654KB

-FINANCIAL INFORMATION

PART I-FINANCIAL INFORMATION 4 Item 1. Condensed Consolidated Financial Statements 4 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) 5 Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) 6 Condensed Consolidated Statements of Cash Flows (Unaudited) 7 Notes to Unaudited Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 25 Item 4.

Controls and Procedures

Controls and Procedures 25

-OTHER INFORMATION

PART II-OTHER INFORMATION 26 Item 1.

Legal Proceedings

Legal Proceedings 26 Item 1A.

Risk Factors

Risk Factors 26 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 26 Item 3. Defaults Upon Senior Securities 26 Item 6. Exhibits 26

SIGNATURES

SIGNATURES 27 2 Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that relate to future events, our future operations or financial performance, or our plans, strategies and prospects. These statements are based on the beliefs and assumptions of our management team. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or performance, are forward-looking statements. These statements may be preceded by, followed by or include the words "believes," "estimates," "expects," "projects," "forecasts," "may," "will," "should," "seeks," "plans," "scheduled," "anticipates" or "intends" or the negative of these terms, or other comparable terminology intended to identify statements about the future, although not all forward-looking statements contain these identifying words. The forward-looking statements are based on projections prepared by, and are the responsibility of, our management team. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about: our ability to access debt and equity markets and raise additional capital when needed; plans and expectations that depend on our ability to continue as a going concern; the success of our collaborations, clinical trials and pre-clinical development efforts and program

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements. HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and par value data) June 30, December 31, 2025 2024 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 786 $ 2,486 Accounts receivable 5 231 Inventory 27 80 Prepaid research and development 53 90 Prepaid expenses and other current assets 246 347 Total current assets 1,117 3,234 Property, plant and equipment, net 8 11 Right-of-use assets, net 245 293 Long-term prepaid contracts 767 904 Total assets $ 2,137 $ 4,442 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 352 $ 452 Accrued and other current liabilities 563 221 Deferred revenue 149 — Insurance premium financing payable 63 253 Operating lease liability 104 95 Total current liabilities 1,231 1,021 Operating lease liability, net of current portion 145 199 Total liabilities 1,376 1,220 Commitments and contingencies (Note 6) Stockholders' equity: Common stock, par value $ 0.01 per share, 60,000,000 shares authorized; 15,918,979 shares issued and outstanding at each of June 30, 2025 and December 31, 2024 159 159 Additional paid-in capital 103,779 102,757 Accumulated deficit ( 103,170 ) ( 99,688 ) Accumulated other comprehensive loss ( 7 ) ( 6 ) Total stockholders' equity 761 3,222 Total liabilities and stockholders' equity $ 2,137 $ 4,442 See accompanying notes to unaudited condensed consolidated financial statements. 4 Table of Contents HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (in thousands, except share and per share data) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Product revenue $ 317 $ 56 $ 362 $ 113 Operating expenses:

View Full Filing

View this 10-Q filing on SEC EDGAR